Literature DB >> 31612254

[Dose de-escalation during adjuvant chemoradiotherapy of HPV-associated oropharyngeal squamous cell carcinoma: the MC1273 phase II study].

Alexander Rühle1,2, Nils H Nicolay3,4.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31612254     DOI： 10.1007/s00066-019-01527-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

3.  Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

Authors:  Pierre Blanchard; Jean Bourhis; Benjamin Lacas; Marshall R Posner; Jan B Vermorken; Juan J Cruz Hernandez; Abderrahmane Bourredjem; Gilles Calais; Adriano Paccagnella; Ricardo Hitt; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

4.  Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.

Authors:  Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote
Journal:  J Clin Oncol       Date:  2019-06-04       Impact factor: 44.544

5.  Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.

Authors:  Qiang Ed Zhang; Qian Wu; Paul M Harari; David I Rosenthal
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

6.  Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.

Authors:  Shao Hui Huang; Bayardo Perez-Ordonez; Fei-Fei Liu; John Waldron; Jolie Ringash; Jonathan Irish; Bernard Cummings; Lillian L Siu; John Kim; Ilan Weinreb; Andrew Hope; Patrick Gullane; Dale Brown; Willa Shi; Brian O'Sullivan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

7.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Authors:  Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

8.  Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients.

Authors:  Marcy A List; Judith Lee Rutherford; John Stracks; Barbara Roa Pauloski; Jerilyn A Logemann; Donna Lundy; Paula Sullivan; William Goodwin; Merrill Kies; Everett E Vokes
Journal:  Head Neck       Date:  2004-02       Impact factor: 3.147

9.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

Authors:  Paul M Harari; Jonathan Harris; Merrill S Kies; Jeffrey N Myers; Richard C Jordan; Maura L Gillison; Robert L Foote; Mitchell Machtay; Marvin Rotman; Deepak Khuntia; William Straube; Qiang Zhang; Kian Ang
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

10.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Authors:  Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321
  10 in total
  2 in total

1.  Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.

Authors:  Clara Dobler; Tina Jost; Markus Hecht; Rainer Fietkau; Luitpold Distel
Journal:  Cells       Date:  2020-09-01       Impact factor: 6.600

Review 2.  De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers-HPV and Beyond.

Authors:  Alexander Rühle; Anca-Ligia Grosu; Nils H Nicolay
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.